Stanford University
Showing 21-30 of 39 Results
-
Andrew Picel, MD
Clinical Associate Professor, Radiology
Current Research and Scholarly InterestsProstate artery embolization (PAE) for the treatment of lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH).
Prophylactic balloon occlusion catheters and uterine artery embolization to reduce blood loss in patients with invasive placenta.
Geniculate artery embolization for relief of osteoarthritis related knee pain. -
Laura Jean Pisani, Ph.D.
Physical Science Research Scientist, Radiology - Diagnostic Radiology
Current Role at StanfordAssociate Director of Stanford Center for Innovation in In vivo Imaging (SCi3), Radiology
Member, Molecular Imaging Program at Stanford -
Sharon Pitteri
Associate Professor (Research) of Radiology (Diagnostic Sciences Laboratory)
On Leave from 01/01/2025 To 03/01/2025Current Research and Scholarly InterestsThe Pitteri laboratory is focused on the discovery and validation of proteins that can be used as molecular indicators of risk, diagnosis, progression, and recurrence of cancer. Proteomic technologies, predominantly mass spectrometry, are used to identify proteins in the blood that are differentially regulated and/or post-translationally modified with disease state. Using human plasma samples, tumor tissue, cancer cell lines, and genetically engineered mouse models, the origins of these proteins are being investigated. A major goal of this research is to define novel molecular signatures for breast and ovarian cancers, including particular sub-types of these diseases. This laboratory is also focused on the identification of proteins with expression restricted to the surface of cancer cells which can be used as novel targets for molecular imaging technologies.
-
Sylvia K. Plevritis, PhD
William M. Hume Professor in the School of Medicine, Professor of Biomedical Data Science and of Radiology
Current Research and Scholarly InterestsMy research program focuses on computational modeling of cancer biology and cancer outcomes. My laboratory develops stochastic models of the natural history of cancer based on clinical research data. We estimate population-level outcomes under differing screening and treatment interventions. We also analyze genomic and proteomic cancer data in order to identify molecular networks that are perturbed in cancer initiation and progression and relate these perturbations to patient outcomes.
